Mechanisms of Immune Activation in Hypertension

高血压的免疫激活机制

• 批准号: 10543181
• 负责人: David G Harrison
• 金额: $ 75.15万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-02-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10543181
• 关键词: Adult; Affect; Antigen-Presenting Cells; Biological Markers; CD8-Positive T-Lymphocytes; Cells; Collaborations; Data; Dendritic Cells; Disease; Experimental Models; Healthcare; Histocompatibility Antigens Class I; Human; Hypertension; IL17 gene; Immunization; Individual; Inflammation; Interferon Type II; Kidney Diseases; Lipids; Major Histocompatibility Complex; Mass Spectrum Analysis; Mitochondria; Mus; Myocardial Infarction; NADPH Oxidase; Natural Immunity; Pathogenicity; Peptides; Process; Proliferating; Proteins; Public Health; Reactive Oxygen Species; Research; Severity of illness; Source; Stroke; T memory cell; T-Cell Activation; T-Cell Receptor; T-Lymphocyte; T-Lymphocyte Subsets; United States; adaptive immunity; adduct; care burden; hypertensive; immune activation; immunogenic; monocyte; neoantigens; novel; oxidation; prevent; programs; single cell sequencing; translational immunology

PROJECT SUMMARY In recent years, it has become apparent that both innate and adaptive immunity contribute to the genesis of hypertension. We have discovered a novel mechanism that underlies activation of adaptive immunity in hypertension, involving the formation of isolevuglandins (isoLGs) in dendritic cells (DCs) and other antigen presenting cells. These lipid oxidation products adduct to proteins, resulting in formation of neoantigens that are processed and presented by major histocompatibility complexes (MHCs). IsoLG-modified proteins are increased in DCs of both mice and humans with hypertension and drive proliferation of subsets of T cells, particularly CD8+ T cells. In this research program, we are examining mechanisms responsible for formation of isoLGs in DCs. We have evidence that isoLGs are formed as a result of both NADPH oxidase activation and by reactive oxygen species generated by the mitochondria in DCs. Using unique mice we have made we are defining potential immunogenic peptides presented in MHC class 1 and determining if there are different peptides derived from mitochondria versus non-mitochondrial sources. Mass spectroscopy will also be employed to determine if similar isoLG modified peptides are presented by monocytes of humans with hypertension. In parallel studies performed in collaboration with Dr. Simon Mallal, the director of the Translational Immunology Core at Vanderbilt, we are characterizing the alpha and beta chain sequences of T cell receptors (TCRα and TCRβ) in activated T cells of both mice and humans using single cell sequencing. This will allow us to produce surrogate T cells (transfectomas) that can be used to determine their responsiveness to isoLG-modified proteins and peptides presented in MHC class 1 of hypertensive mice. We have recently shown that hypertensive humans have a striking increase in circulating memory T cells that produce IL-17A and IFN-γ compared to matched controls. Data from single cell sequencing will identify the TCRα and TCRβ of these cells and to produce transfectomas expressing these sequences and to determine if they are also responsive to isoLG modified proteins presented in the context of APCs from the same individual. Identifying specific neoantigens in hypertension will provide an enormous advance in understanding this disease. These could serve as biomarkers of disease severity and be used to detect pathogenic T cells in hypertension. Ultimately immunization approaches could be employed to treat or prevent hypertension. Specific therapies to reduce isoLG formation have proven effective in experimental models and have substantial promise for treatment of human hypertension.

项目总结